157 related articles for article (PubMed ID: 22746102)
21. Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis.
Ramaswami R; Tagawa T; Mahesh G; Serquina A; Koparde V; Lurain K; Dremel S; Li X; Mungale A; Beran A; Ohler ZW; Bassel L; Warner A; Mangusan R; Widell A; Ekwede I; Krug LT; Uldrick TS; Yarchoan R; Ziegelbauer JM
J Transl Med; 2023 Sep; 21(1):653. PubMed ID: 37740179
[TBL] [Abstract][Full Text] [Related]
22. HMGB1, a potential regulator of tumor microenvironment in KSHV-infected endothelial cells.
Lee MJ; Park J; Choi S; Yoo SM; Park C; Kim HS; Lee MS
Front Microbiol; 2023; 14():1202993. PubMed ID: 37520371
[TBL] [Abstract][Full Text] [Related]
23. KSHV vIL-6 promotes SIRT3-induced deacetylation of SERBP1 to inhibit ferroptosis and enhance cellular transformation by inducing lipoyltransferase 2 mRNA degradation.
Zhou J; Wang T; Zhang H; Liu J; Wei P; Xu R; Yan Q; Chen G; Li W; Gao SJ; Lu C
PLoS Pathog; 2024 Mar; 20(3):e1012082. PubMed ID: 38470932
[TBL] [Abstract][Full Text] [Related]
24. Single-Cell Transcriptomic Analysis of Kaposi Sarcoma.
Rauch DA; Ramos PV; Khanfar M; Harding J; Joseph A; Griffith O; Griffith M; Ratner L
bioRxiv; 2024 May; ():. PubMed ID: 38746135
[TBL] [Abstract][Full Text] [Related]
25. Kaposi's sarcoma herpesvirus oncogenesis is a notch better in 3D.
Mesri EA; Cesarman E
Cell Host Microbe; 2011 Dec; 10(6):529-31. PubMed ID: 22177556
[TBL] [Abstract][Full Text] [Related]
26. Proliferation status defines functional properties of endothelial cells.
Lipps C; Badar M; Butueva M; Dubich T; Singh VV; Rau S; Weber A; Kracht M; Köster M; May T; Schulz TF; Hauser H; Wirth D
Cell Mol Life Sci; 2017 Apr; 74(7):1319-1333. PubMed ID: 27853834
[TBL] [Abstract][Full Text] [Related]
27. Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients.
Dai L; Lu YC; Chen J; Plaisance-Bonstaff K; Mu S; Forrest JC; Whitby D; Post SR; Qin Z
Front Microbiol; 2022; 13():882520. PubMed ID: 35516440
[TBL] [Abstract][Full Text] [Related]
28. N-Acetyl cysteine abrogates silver-induced reactive oxygen species in human cells without altering silver-based antimicrobial activity.
Shah KN; Shah PN; Mullen AR; Chen Q; Southerland MR; Chirra B; DeBerardinis RJ; Cannon CL
Toxicol Lett; 2020 Oct; 332():118-129. PubMed ID: 32659471
[TBL] [Abstract][Full Text] [Related]
29. Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy.
Li F; Cao D; Gu W; Li D; Liu Z; Cui L
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474177
[TBL] [Abstract][Full Text] [Related]
30. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.
Eason AB; Sin SH; Shah M; Yuan H; Phillips DJ; Droste M; Shamshiev A; Dittmer DP
PLoS One; 2020; 15(5):e0233116. PubMed ID: 32407363
[TBL] [Abstract][Full Text] [Related]
31. The adhesion GPCR BAI1 mediates macrophage ROS production and microbicidal activity against Gram-negative bacteria.
Billings EA; Lee CS; Owen KA; D'Souza RS; Ravichandran KS; Casanova JE
Sci Signal; 2016 Feb; 9(413):ra14. PubMed ID: 26838550
[TBL] [Abstract][Full Text] [Related]
32. Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis.
Mesri EA; Cavallin LE; Ashlock BM; Leung HJ; Ma Q; Goldschmidt-Clermont PJ
Immunol Res; 2013 Dec; 57(1-3):159-65. PubMed ID: 24203444
[TBL] [Abstract][Full Text] [Related]
33. Viral G Protein-Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases.
De Groof TWM; Elder EG; Siderius M; Heukers R; Sinclair JH; Smit MJ
Pharmacol Rev; 2021 Apr; 73(2):828-846. PubMed ID: 33692148
[TBL] [Abstract][Full Text] [Related]
34. KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma.
Medina MV; D Agostino A; Ma Q; Eroles P; Cavallin L; Chiozzini C; Sapochnik D; Cymeryng C; Hyjek E; Cesarman E; Naipauer J; Mesri EA; Coso OA
PLoS Pathog; 2020 Oct; 16(10):e1009006. PubMed ID: 33057440
[TBL] [Abstract][Full Text] [Related]
35. In Vitro Studies of Pegylated Magnetite Nanoparticles in a Cellular Model of Viral Oncogenesis: Initial Studies to Evaluate Their Potential as a Future Theranostic Tool.
Principe G; Lezcano V; Tiburzi S; Miravalles AB; Rivero PS; Montiel Schneider MG; Lassalle V; González-Pardo V
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839809
[TBL] [Abstract][Full Text] [Related]
36. A major role for Nrf2 transcription factors in cell transformation by KSHV encoded oncogenes.
Sapochnik D; Raimondi AR; Medina V; Naipauer J; Mesri EA; Coso O
Front Oncol; 2022; 12():890825. PubMed ID: 36212441
[TBL] [Abstract][Full Text] [Related]
37. Metabolic landscapes in sarcomas.
Miallot R; Galland F; Millet V; Blay JY; Naquet P
J Hematol Oncol; 2021 Jul; 14(1):114. PubMed ID: 34294128
[TBL] [Abstract][Full Text] [Related]
38. A Non-Coding RNA Network Involved in KSHV Tumorigenesis.
Naipauer J; García Solá ME; Salyakina D; Rosario S; Williams S; Coso O; Abba MC; Mesri EA; Lacunza E
Front Oncol; 2021; 11():687629. PubMed ID: 34222014
[TBL] [Abstract][Full Text] [Related]
39. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
Cao Y; Xie L; Shi F; Tang M; Li Y; Hu J; Zhao L; Zhao L; Yu X; Luo X; Liao W; Bode AM
Signal Transduct Target Ther; 2021 Jan; 6(1):15. PubMed ID: 33436584
[TBL] [Abstract][Full Text] [Related]
40. Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism.
Calderon A; Soldan SS; De Leo A; Deng Z; Frase DM; Anderson EM; Zhang Y; Vladimirova O; Lu F; Leung JC; Murphy ME; Lieberman PM
Oncotarget; 2020 Nov; 11(46):4224-4242. PubMed ID: 33245718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
